Table 2.
Partially and fully adjusted HRs for risk of VTE in AD cohorts compared to a matched non-AD cohort
| No. of events | Partially adjusted HRa | Fully adjusted HRb | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Overall AD cohort vs. non AD cohort | |||||
| VTE | 2148 | 1.00 (0.92, 1.09) | 0.95 | 0.77 (0.69, 0.85) | < 0.001 |
| PE | 711 | 0.87 (0.75, 1.01) | 0.07 | 0.66 (0.56, 0.79) | < 0.001 |
| DVT | 1674 | 1.04 (0.95, 1.15) | 0.40 | 0.81 (0.72, 0.91) | < 0.001 |
| Sub-cohort with moderate-to-severe AD vs. non-AD cohort | |||||
| VTE | 1859 | 1.24 (1.13, 1.36) | < 0.001 | 0.95 (0.85, 1.07) | 0.41 |
| PE | 629 | 1.11 (0.95, 1.30) | 0.19 | 0.83 (0.69, 1.01) | 0.07 |
| DVT | 1438 | 1.28 (1.16, 1.42) | < 0.001 | 1.00 (0.88, 1.14) | 0.99 |
AD atopic dermatitis, CI confidence interval, HR hazard ratio
aAdjusted for matching variables (5-year age category, sex, and calendar year)
bAdjusted for 5-year age category, sex, calendar year, healthcare utilization, medications (hormone therapy, systemic corticosteroid, methotrexate, statins, antipsychotics, and cyclooxygenase-2 inhibitors), and comorbidities (cancer, trauma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn’s disease, and obesity)